CD38 inhibitor / NAD metabolism small-molecule program
preclinicalDevelop small-molecule drugs against an aging-related target linked to NAD metabolism, including CD38 inhibition for disease and disorder treatment.
Small-molecule heteroaryl amide CD38 inhibitors discovered/developed from NAD metabolism research and accelerated using Insilico Medicine's drug development engine; preclinical efficacy evaluated in a collagen-induced arthritis mouse model.
Patent application for heteroaryl amide inhibitors of CD38 was published on 2022-04-14; a 2023 conference abstract reported therapeutic effects of a newly developed small-molecule CD38 inhibitor in a collagen-induced arthritis mouse model.
Preclinical mouse-model abstract reports therapeutic effects in collagen-induced arthritis; no detailed efficacy data were supplied.